IPP Bureau

Bengaluru docs perform world’s first single-stage robotic heart bypass & prostate cancer surgery
Bengaluru docs perform world’s first single-stage robotic heart bypass & prostate cancer surgery

By IPP Bureau - January 24, 2026

Amway India launches ‘Beyond Biotin’ Nutrilite Biotin C Plus to support skin, hair, nail health
Amway India launches ‘Beyond Biotin’ Nutrilite Biotin C Plus to support skin, hair, nail health

By IPP Bureau - January 24, 2026

The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc

Yugap Wellness bolsters scientific leadership with Dr Satish Singh appointment
Yugap Wellness bolsters scientific leadership with Dr Satish Singh appointment

By IPP Bureau - January 24, 2026

A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods

Rising demand for obesity drugs hits employer healthcare budgets, says Howden Report
Rising demand for obesity drugs hits employer healthcare budgets, says Howden Report

By IPP Bureau - January 24, 2026

The research shows 93% of global companies now cover weight-management drugs in their health insurance plans

Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India

By IPP Bureau - January 24, 2026

Company to launch product after the expiry of semaglutide patent in India

Lupin receives highest ESG rating from CDP for climate change and water security
Lupin receives highest ESG rating from CDP for climate change and water security

By IPP Bureau - January 24, 2026

Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability

Cipla reports consolidated PAT of Rs. 675.80 Cr
Cipla reports consolidated PAT of Rs. 675.80 Cr

By IPP Bureau - January 24, 2026

Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025

Laurus Labs reports consolidated Q3 net profit of Rs. 251.66 Cr
Laurus Labs reports consolidated Q3 net profit of Rs. 251.66 Cr

By IPP Bureau - January 24, 2026

Laurus Labs has reported total income of Rs. 1,784.05 crore during the period ended December 31, 2025

Jagsonpal Pharmaceuticals posts Q3 FY26 profit at Rs. 10.95 Cr
Jagsonpal Pharmaceuticals posts Q3 FY26 profit at Rs. 10.95 Cr

By IPP Bureau - January 24, 2026

Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025

Functional Gut Clinic launches UK’s first boutique GI clinical trials division
Functional Gut Clinic launches UK’s first boutique GI clinical trials division

By IPP Bureau - January 23, 2026

Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced

Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery
Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery

By IPP Bureau - January 23, 2026

This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market

FDA nod to Boehringer Ingelheim's heart disease treatment for dogs 'Vetmedin'
FDA nod to Boehringer Ingelheim's heart disease treatment for dogs 'Vetmedin'

By IPP Bureau - January 23, 2026

VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs

G Square acquires majority stake in Finnish surgical solutions leader Serres
G Square acquires majority stake in Finnish surgical solutions leader Serres

By IPP Bureau - January 23, 2026

Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies
Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies

By IPP Bureau - January 23, 2026

The partnership initially will focus on cardiovascular and kidney diseases

Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline
Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline

By IPP Bureau - January 23, 2026

The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025

Latest Stories

Interviews

Packaging